MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Edwards Lifesciences Corp

Closed

SectorHealthcare

72.08 0.45

Overview

Share price change

24h

Current

Min

70.64

Max

72.34

Key metrics

By Trading Economics

Income

-2.7B

346M

Sales

31M

1.4B

P/E

Sector Avg

30.714

63.778

EPS

0.59

Profit margin

24.989

Employees

15,800

EBITDA

55M

484M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+7.89% upside

Dividends

By Dow Jones

Next Earnings

23 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-1.1B

42B

Previous open

71.63

Previous close

72.08

News Sentiment

By Acuity

22%

78%

55 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Edwards Lifesciences Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lip 2024, 13:57 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences to Buy Innovalve for $300 Million

25 paź 2024, 09:10 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

25 paź 2024, 08:35 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, Capri, Western Digital, Spirit Airlines, Deckers, Coursera, and More -- Barrons.com

3 wrz 2024, 20:38 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences: After Recent Accelerated Repurchase Agreement and August Buybacks Via 10b5-1 Agreement and Open Market Repurchases, Company Has $1.4B in Remaining Authorization

3 wrz 2024, 20:37 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Completes Sale of Critical Care Group to Becton Dickinson for $4.2B

3 wrz 2024, 20:36 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Authorizes $1.5B of Additional Share Repurchases

25 lip 2024, 09:02 UTC

Earnings
Hot Stocks

Stocks to Watch Thursday: Ford, IBM, Chipotle, American Airlines -- WSJ

25 lip 2024, 08:40 UTC

Top News

These Stocks Are Moving the Most Today: Ford, Tesla, Alphabet, Nvidia, Super Micro, IBM, ServiceNow, Chipotle, and More -- Barrons.com

24 lip 2024, 20:17 UTC

Earnings

Edwards Lifesciences: Expects 2024 Edwards Sales Growth of 8% to 10% >EW

24 lip 2024, 20:15 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

24 lip 2024, 20:15 UTC

Earnings

Edwards Lifesciences 2Q Sales $1.39B >EW

24 lip 2024, 20:15 UTC

Earnings

Edwards Lifesciences 2Q Net $366.3M >EW

24 lip 2024, 20:15 UTC

Earnings

Edwards Lifesciences 2Q Adj EPS 70c >EW

24 lip 2024, 20:15 UTC

Earnings

Edwards Lifesciences 2Q EPS 61c >EW

15 lip 2024, 13:42 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences to Buy Innovalve for $300M

15 lip 2024, 13:01 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences: SAPIEN M3 Remains on Track to Become First Approved Transfemoral TMVR System in Europe by End of 2025 >EW

15 lip 2024, 13:01 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences: Acquisition Enhances TMVR Technologies to Address Large Unmet Structural Heart Patient Needs >EW

15 lip 2024, 13:00 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences to Acquire Innovalve Bio Medical Ltd., Early-Stage Transcatheter Mitral Valve Replacement Co >EW

15 lip 2024, 13:00 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences To Acquire Innovalve >EW

4 cze 2024, 17:26 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Deal A Clear Win For Becton Dickinson, Analysts Say -- Analysis

3 cze 2024, 13:26 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences Stock Nears Breakout On A Surprise $4.2 Billion Deal -- IBD

3 cze 2024, 12:25 UTC

Top News
Acquisitions, Mergers, Takeovers

Becton Dickinson to Acquire Edwards Lifesciences' Unit for $4.2 Billion in Cash -- Update

3 cze 2024, 11:03 UTC

Top News
Acquisitions, Mergers, Takeovers

Becton Dickinson to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2B in Cash

3 cze 2024, 10:40 UTC

Acquisitions, Mergers, Takeovers

Edwards Lifesciences To Sell Its Critical Care Product Group For $4.2 Billion To Becton Dickinson -- MarketWatch

3 cze 2024, 10:32 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson: Acquired Business Has About 4,500 Employees >BDX EW

3 cze 2024, 10:31 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson: Acquired Business Generated More Than $900 Million Revenue in 2023 >BDX

3 cze 2024, 10:31 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson: Deal Expands Portfolio of Smart Connected Care Solutions >BDX EW

3 cze 2024, 10:30 UTC

Acquisitions, Mergers, Takeovers

Becton Dickinson to Buy Edwards Lifesciences Critical Care Product Group for $4.2 Billion >BDX EW

3 cze 2024, 10:30 UTC

Acquisitions, Mergers, Takeovers

BD To Acquire Edwards Lifesciences' Critical Care Product Group For $4.2 Billion To Expand Smart Connected Care Solutions And Become An Advanced Monitoring Technology Leader >BDX EW

26 kwi 2024, 20:10 UTC

Earnings

This 'Critical' Business Helped Edwards Lifesciences Offset Its TAVR Miss -- IBD

Peer Comparison

Price change

Edwards Lifesciences Corp Forecast

Price Target

By TipRanks

7.89% upside

12 Months Forecast

Average 77.54 USD  7.89%

High 90 USD

Low 60 USD

Based on 19 Wall Street analysts offering 12 month price targets forEdwards Lifesciences Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

19 ratings

7

Buy

11

Hold

1

Sell

Technical Score

By Trading Central

71.2 / 72.48Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

55 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.